Premarket Movers | Denny's Soars 48%; Hims & Hers Gains 3%; Grab Drops 4%; Navitas Sinks 15%; Sarepta Plunges 37%

Restaurant chain Denny's announced on Monday it would be acquired by a group comprising TGI Fridays-owner TriArtisan Capital Advisors in a $620 million deal, including debt. Denny's shares surged 47.5% in premarket trading on Tuesday.

Exact Sciences shares jumped 4.7% in premarket trading on Tuesday after the cancer screening provider reported third-quarter results that exceeded analyst expectations and raised its full-year outlook.

Hims & Hers Health beat Wall Street estimates for third-quarter revenue on Monday, as the telehealth company added subscribers and expanded its personalized healthcare offerings. Hims & Hers said it was in active talks with Novo to offer Wegovy injections and, once approved, an oral version through its platform. The shares gained 3.2% in premarket trading on Tuesday.

Baidu shares rose 3% in premarket trading on Tuesday. The rally follows reports that Baidu is accelerating its global autonomous ride-hailing business. As of October 31, its Apollo Go division recorded over 250,000 weekly fully driverless ride-hailing orders—a scale comparable to Waymo’s paid ride volume in the U.S. as of late April this year.

Grab beat analysts' expectations for third-quarter revenue on Monday, supported by robust consumer spending on ride-hailing and food-delivery services as its platform expansion draws in additional users. Third-quarter revenue for Grab's deliveries segment stood at $465 million, compared with estimates of $470 million. The shares dropped 4.3% in premarket trading on Tuesday.

Energy Fuels reported quarterly losses of seven cents per share, which missed the Street estimate for losses of six cents. The shares sank 10.1% in premarket trading.

Navitas Semiconductor shares tumbled 15.4% in premarket trading on Tuesday after the next-generation power semiconductor company reported third-quarter results that missed analyst expectations and announced a strategic pivot away from consumer markets.

Sarepta said on Monday that its late-stage study testing two gene-targeted therapies for Duchenne muscular dystrophy did not meet the main goal, sending its shares plummeting 36.9% in premarket trading on Tuesday.